Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work
A high-profile collaboration with Takeda back in late 2018 bestowed upon Enterome some pharma validation and significant cash — $50 million upfront and another …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
